Displaying 1 - 12 of 12
Liver Tumours
6

AstraZeneca: Evolution Of HCC Management: Clinical Considerations For Mdt-Directed Care And Treatment Selection - EASL Liver Cancer Summit 2024

View
Liver Tumours
6

AstraZeneca: Evolution Of HCC Management: Clinical Considerations For Mdt-Directed Care And Treatment Selection - EASL Liver Cancer Summit 2024

View
Liver Tumours
6

AstraZeneca: Evolution Of HCC Management: Clinical Considerations For Mdt-Directed Care And Treatment Selection - EASL Liver Cancer Summit 2024

View
Liver Tumours
6

AstraZeneca: Evolution Of HCC Management: Clinical Considerations For Mdt-Directed Care And Treatment Selection - EASL Liver Cancer Summit 2024

View
Liver Tumours
6

AstraZeneca: Evolution Of HCC Management: Clinical Considerations For Mdt-Directed Care And Treatment Selection - EASL Liver Cancer Summit 2024

View
Liver Tumours
6

AstraZeneca: Evolution Of HCC Management: Clinical Considerations For Mdt-Directed Care And Treatment Selection - EASL Liver Cancer Summit 2024

View
Metabolism, Alcohol & Toxicity
6

Perspectum: Advances in non-invasive imaging for NAFLD / NASH - ILC 2022

View
Metabolism, Alcohol & Toxicity
6

Perspectum: Advances in non-invasive imaging for NAFLD / NASH - ILC 2022

View
Metabolism, Alcohol & Toxicity
6

Perspectum: Advances in non-invasive imaging for NAFLD / NASH - ILC 2022

View
Metabolism, Alcohol & Toxicity
6

Perspectum: Advances in non-invasive imaging for NAFLD / NASH - ILC 2022

View
Metabolism, Alcohol & Toxicity
6

Perspectum: Advances in non-invasive imaging for NAFLD / NASH - ILC 2022

View
Immune-Mediated and Cholestatic Diseases
1

Ipsen: Current challenges in Primary Biliary Cholangitis (PBC): Debating the care odyssey - ILC 2022

View
Displaying 1 - 12 of 12